<DOC>
	<DOCNO>NCT00764166</DOCNO>
	<brief_summary>The primary objective evaluate PSA ( biochemical ) progression-free survival ( PFS ) high-risk metastasis-free PC patient , treat LH-RH agonist one year without docetaxel prior radical prostatectomy ( RP ) radiotherapy ( RT ) . The study power 80 % detect 25 % improvement biochemical PFS total sample size estimate 252 patient , two-sided type I error rate 5 % ( non-parametric method .</brief_summary>
	<brief_title>A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel</brief_title>
	<detailed_description>Docetaxel show active metastatic hormone-refractory prostate cancer ( PC ) phase III trial ( 1-2 ) . It likely demonstrate substantial role management early-stage PC patient neoadjuvant adjuvant setting , clinical trial underway.â€¢53 % men undergo radical prostatectomy develop prostate-specific antigen ( PSA ) elevations 10 year follow surgery , approximately 77 % recurrence occur within first 2 years.A prospective , multicenter , national , randomize , two-arm , phase III study compare hormonal treatment ( LH-RH agonist alone ) without docetaxel design evaluate interest chemotherapy non-metastatic prostate cancer patient high risk systemic recurrence initial treatment ( radical prostatectomy radiotherapy ) . 1 . PETRYLAK DP , et al : Docetaxel estramustine compare mitoxantrone prednisone advance refractory prostate cancer . N Engl J Med 351:1513-1520 , 2004 2 . TANNOCK IF , de Wit R , Berry WR , et al : Docetaxel plus prednisone mitoxantrone plus prednisone advanced prostate cancer . N Engl J Med 351:1502-1512 , 2004</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>Histologically document adenocarcinoma prostate Previous treatment either radical prostatectomy radiation therapy Salvage radiotherapy local relapse allow Neoadjuvant per radiotherapy Hormonal therapy allow case 6 month freeinterval first rise PSA Life expectancy 12 month Non metastatic disease document image include radionuclide bone scan ECOG performance status 01 ANC &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 SGOT and/or SGPT may 2.5 x ULN Patients high risk biological relapse define : Gleason &gt; 8 PSADT &lt; 6 month Positive surgical margin PSA velocity &gt; 0.75 ng/mL/year Pathological pelvic lymph node involvement ( pN+ ) Time initial treatment inclusion &lt; 12 month Prior chemotherapy taxanes estramustine phosphate Documented local recurrence prostate cancer document metastatic disease History malignancy within last 5 year curatively treat basal cell carcinoma skin Active infection Significant cardiac disease , angina pectoris myocardial infarction within twelve month Clinically significant neuropathy Medical condition require use concomitant corticosteroid Prohibited concomitant therapy experimental drug . Participation another clinical trial period &lt; 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>PSA ( biochemical )</keyword>
	<keyword>Progression- free Survival</keyword>
	<keyword>Clinical progress</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Tolerance treatment</keyword>
	<keyword>Quality Live</keyword>
</DOC>